rs907091 — IKZF3 IKZF3 miRNA Binding Region Variant

A 3'UTR variant in IKZF3 that alters miR-326 binding affinity, reducing Aiolos transcription factor expression in a T-allele-dependent manner and increasing susceptibility to systemic autoimmune disease through impaired B-cell maturation and immune homeostasis

See your personal result for IKZF3

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

IKZF3 miRNA Regulation — When B-Cell Guardian Aiolos Is Silenced

IKZF3 encodes Aiolos, a zinc finger transcription factor in the Ikaros family that acts as a guardian of immune homeostasis. Aiolos is expressed throughout lymphocyte development and plays essential roles in B-cell maturation, plasma cell differentiation, and — crucially — suppression of aberrant autoimmune responses. Aiolos-deficient mice spontaneously develop a lupus-like syndrome11 Aiolos-deficient mice spontaneously develop a lupus-like syndrome
Sun et al. J Immunol 2003; knockout mice produce anti-dsDNA antibodies and develop immune complex-mediated glomerulonephritis characteristic of human SLE, establishing that sufficient Aiolos expression is required to keep autoreactive B cells in check.

The rs907091 variant does not change the Aiolos protein itself — it sits in the 3' untranslated region22 3' untranslated region
3'UTR — the section of mRNA after the stop codon that regulates mRNA stability, translation efficiency, and susceptibility to microRNA silencing of the IKZF3 transcript. The T allele at this position creates or enhances a binding site for miR-32633 miR-326
A microRNA that silences target mRNAs by binding to complementary sequences in the 3'UTR and inhibiting translation or promoting mRNA degradation, the net effect being greater suppression of Aiolos protein output in T-allele carriers.

The Mechanism

Ghanbari et al. 201544 Ghanbari et al. 2015
Screening of 11,067 cardio-metabolic loci for miRNA binding site variants; rs907091 was one of only two variants validated by luciferase reporter assay as showing gain-of-function miRNA activity — the T allele enhanced miR-326 suppression of IKZF3 demonstrated through experimental reporter assays that the T allele at rs907091 enhances miR-326 activity at the IKZF3 3'UTR, amplifying post-transcriptional silencing. Because IKZF3 lies on the minus strand, the plus-strand T allele corresponds to an A substitution on the coding strand within the 3'UTR — this change creates a better match to the miR-326 seed sequence and increases miRNA-mediated repression.

The result is dose-dependent: each T allele adds another layer of miR-326 silencing, so TT homozygotes produce less Aiolos protein than CT heterozygotes, who in turn produce less than CC homozygotes.

Reduced Aiolos output has two major downstream consequences. First, it impairs B-cell maturation checkpoints55 B-cell maturation checkpoints
Fedl et al. Nat Immunol 2024 — Aiolos co-operates with Ikaros to repress surrogate light-chain genes in small pre-B cells; without this repression step, ordered B-cell development is disrupted, allowing potentially autoreactive B cells to escape regulatory gates. Second, reduced Aiolos shifts the balance toward aberrant germinal center formation and spontaneous antibody production, as documented in Aiolos-null mice. In eosinophils, Aiolos controls CCR3 expression and tissue migration66 CCR3 expression and tissue migration
Felton et al. Mucosal Immunol 2021; Aiolos-deficient eosinophils show reduced CCR3 surface expression and impaired chemotaxis, with blunted ERK/MAPK and actin polymerization responses to CCL11, making IKZF3 level relevant to eosinophil-driven allergic disease as well.

The Evidence

Population genetic studies in Chinese Han cohorts have directly associated rs907091 with systemic lupus erythematosus risk. Cai et al. PLoS One 201477 Cai et al. PLoS One 2014
310 SLE cases vs 341 healthy controls; four IKZF3 SNPs typed including rs907091 found that the CC genotype was significantly underrepresented in SLE patients relative to controls (p=0.001), and that the C allele itself was lower-frequency in cases (p=0.015). This protective effect is consistent with the mechanistic model: more Aiolos (CC genotype, lower miR-326 suppression) = better B-cell homeostasis = lower autoimmune risk.

A second case-control study by Ye et al. 201688 Ye et al. 2016
213 SLE patients vs 234 controls in Han Chinese from southern China; PCR-RFLP genotyping provided more granular analysis, showing that the CA (CT on plus strand) genotype specifically protected against SLE renal involvement (OR=0.59, 95% CI 0.35–0.98, p=0.043) and anti-SSB antibody production (OR=0.41, 95% CI 0.18–0.96, p=0.040). Anti-SSB (anti-La) antibodies are a marker of B-cell dysregulation in SLE, directly linking this variant to the Aiolos B-cell regulation pathway.

At a population level, the broader IKZF3–ZPBP2 chromosomal region reached genome-wide significance for SLE susceptibility in a multiracial GWAS of nearly 16,000 individuals99 multiracial GWAS of nearly 16,000 individuals
Lessard et al. Am J Hum Genet 2012; p=3.48×10⁻¹⁰ for the IKZF3-ZPBP2 locus across European, African American, Asian, Hispanic, Gullah, and Amerindian populations, confirming that IKZF3 region variants are a replicated susceptibility signal beyond any single population.

The evidence is strongest in East Asian populations where rs907091 has been directly studied; the biological mechanism is well-established (Aiolos deficiency → autoimmunity in mice; T allele → enhanced miR-326 silencing → less Aiolos). Evidence from other ancestries and for RA specifically is less direct, and most studies focus on the closely linked rs2872507 at this locus.

Practical Actions

For TT homozygotes — who produce the least Aiolos and have the highest miR-326 suppression of IKZF3 — the primary actionable concern is elevated susceptibility to B-cell-mediated autoimmune disease, particularly SLE and related antibody-positive conditions. The most valuable actions are periodic autoantibody screening (ANA, anti-dsDNA) and prompt evaluation of any musculoskeletal or mucocutaneous symptoms suggesting early lupus. There is currently no approved intervention that specifically restores Aiolos expression, though lenalidomide and related IMiD drugs paradoxically degrade Aiolos via CRBN-mediated ubiquitination — these are not relevant as preventive treatments.

For eosinophilic or atopic conditions in carriers of the T allele, the connection to Aiolos-dependent eosinophil CCR3 expression and tissue recruitment provides biological rationale for reduced eosinophilic tissue inflammation, though direct clinical evidence linking rs907091 genotype to eosinophil counts in humans is not yet established.

Interactions

rs907091 sits within the 17q21 chromosomal region and is in partial linkage disequilibrium with rs2872507 (IKZF3 regulatory variant) and several ORMDL3/GSDMB SNPs at this locus. The rs2872507 A allele also confers autoimmune risk (RA, Crohn's, Graves') through a different regulatory mechanism affecting the ORMDL3-GSDMB locus. Carriers of risk alleles at both rs907091 and rs2872507 may face compounded IKZF3 functional impairment affecting distinct aspects of lymphocyte regulation.

Compound risk with PTPN22 rs2476601 (T-cell tolerance) is biologically plausible: PTPN22 R620W disrupts T-cell signaling thresholds while IKZF3 rs907091 TT impairs B-cell maturation oversight — two independent pathways converging on autoimmune susceptibility.

Genotype Interpretations

What each possible genotype means for this variant.

CC Full Aiolos Expression Beneficial

Two protective C alleles — normal Aiolos expression with lowest miR-326 suppression

The CC genotype represents the lowest miR-326 binding affinity configuration at the IKZF3 3'UTR. Without T-allele enhancement of the miR-326 binding site, IKZF3 mRNA is less susceptible to post-transcriptional silencing, allowing Aiolos protein to accumulate to its normal physiological level in B cells, T cells, and eosinophils.

In the Cai et al. 2014 case-control study (310 SLE cases, 341 controls), the CC genotype showed p=0.001 for reduced frequency in SLE cases — the strongest single-locus signal among the four IKZF3 SNPs studied, indicating that two protective C alleles provide meaningful protection against SLE at the population level. This protective effect is mechanistically attributable to better B-cell maturation and suppression of aberrant germinal center formation.

CT Partial miR-326 Silencing Intermediate

One T risk allele — moderately reduced Aiolos expression via enhanced miR-326 activity

Heterozygous CT carriers express IKZF3 from both chromosomes, but the T-allele copy is under greater miR-326 suppression. The net Aiolos protein level sits between CC and TT extremes. The dose-dependent (additive) nature of this variant means the CT genotype confers intermediate autoimmune susceptibility — modestly elevated relative to CC, but substantially lower than TT.

The anti-SSB finding from Ye et al. (OR=0.41 in dominant model) is notable because anti-SSB/anti-La antibodies are produced by dysregulated B cells and mark early SLE-spectrum autoimmunity. The heterozygous protective effect on this specific autoantibody profile suggests that even one protective C allele provides meaningful restraint on autoreactive B-cell activation.

TT Peak miR-326 Silencing High Risk

Two T risk alleles — greatest miR-326-mediated suppression of Aiolos, highest autoimmune susceptibility

The TT genotype creates the strongest miR-326 binding configuration at both IKZF3 alleles, maximally suppressing Aiolos translation. This mirrors the biological consequence of Aiolos deficiency in mouse models — where loss of IKZF3 leads to B-cell hyperproliferation, spontaneous germinal center formation, anti-dsDNA antibody production, and immune complex glomerulonephritis (Sun et al. J Immunol 2003).

The Ye et al. 2016 study specifically found that the CA (CT on plus strand) genotype reduced SLE renal involvement (OR=0.59) and anti-SSB positivity (OR=0.41), meaning the TT genotype — lacking the protective C allele entirely — confers the reverse: higher susceptibility to lupus nephritis and anti-SSB antibody production. These are markers of severe, organ-threatening SLE, making the TT genotype actionably important for proactive monitoring.

In eosinophil biology, Aiolos controls CCR3 expression and tissue migration. Lower Aiolos from TT status would theoretically reduce CCR3-driven eosinophil recruitment to allergic tissues — a potentially paradoxical partial protection against eosinophilic tissue inflammation at the cost of impaired B-cell homeostasis. Human clinical data connecting TT genotype to eosinophil levels are not yet available.